Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non–Small Cell Lung Cancer

Published:2019-09-20 Issue:9 Volume:2 Page:e1911895
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Chen Yu¹²³,Chen Gang¹⁴,Li Jin⁵,Huang Ying-Ying⁶,Li Yi⁶,Lin Jing¹²³,Chen Li-Zhu²³,Lu Jian-Ping⁴,Wang Yu-Qi⁵,Wang Chang-Xi⁵,Pan Leong Kin⁷⁸,Xia Xue-Feng⁵,Yi Xin⁵,Chen Chuan-Ben¹²⁹,Zheng Xiong-Wei¹⁴,Guo Zeng-Qing¹²³,Pan Jian-Ji¹²⁹

Affiliation:

1. Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China

2. Cancer Bio-immunotherapy Center, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, China

3. Department of Medical Oncology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, China

4. Department of Pathology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, China

5. Geneplus-Beijing Institute, Beijing, China

6. Fujian Medical University Cancer Hospital, Fuzhou, China

7. China Certification and Inspection Group, Kuok Kim Medical Center III, Macao, China

8. Hui Xian Medical Center, Macao, China

9. Department of Radiation Oncology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, China

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2751557/chen_2019_oi_190455.pdf

Reference42 articles.

1. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer.;Reck;N Engl J Med,2016

2. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer.;Carbone;N Engl J Med,2017

3. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.;Herbst;Lancet,2016

4. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.;Fehrenbacher;Lancet,2016

5. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.;Borghaei;N Engl J Med,2015

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ATM inhibition enhance immunotherapy by activating STING signaling and augmenting MHC Class I;Cell Death & Disease;2024-07-20

2. Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities;Annals of Oncology;2024-06

3. Ginsenoside Rg5 as an anticancer drug: a comprehensive review on mechanisms, structure–activity relationship, and prospects for clinical advancement;Pharmacological Reports;2024-03-25

4. Single-cell RNA sequencing integrated with bulk RNA sequencing analysis identifies a tumor immune microenvironment-related lncRNA signature in lung adenocarcinoma;BMC Biology;2024-03-22

5. ATM—the gene at the moment in non-small cell lung cancer;Translational Lung Cancer Research;2024-03